Promising

Novel ADC Promising in Tough-to-Treat Ovarian Cancer

Novel ADC Promising in Robust-to-Deal with Ovarian Most cancers

PHOENIX — Mirvetuximab soravtansine monotherapy demonstrated anti-tumor activity in previously treated patients with folate receptor alpha (FRα)-high platinum-resistant ovarian cancer, a researcher said here. In the phase III SORAYA trial, treatment with the investigational mirvetuximab resulted in an objective response rate (ORR) of 32.4% (95% CI 23.6%-42.2%) in 106 patients, all of whom received prior…